As global health authorities push for earlier HIV diagnosis, diagnostic manufacturers are accelerating development of p24 antigen-based testing platforms, with fourth-generation assays now reaching commercial maturity across multiple markets.

The p24 antigen, a viral capsid protein, typically becomes detectable 10 to 14 days after HIV infection — days before antibodies emerge. This biological advantage has made p24 a cornerstone of fourth-generation HIV testing strategies, which simultaneously detect both p24 antigen and HIV antibodies to narrow the diagnostic window period.

Commercial Momentum

At WHX Labs Bangkok 2026, Chinese diagnostics manufacturer Wondfo presented its fourth-generation HIV rapid test to Thai Prime Minister Anutin Charnvirakul, highlighting the assay‘s ability to detect infection approximately one week earlier than antibody-only tests. The company reported 100% sensitivity and 99.71% specificity for the combined HIV-1/2 antibody and p24 antigen assay.

In the United States, regulatory approvals have kept pace. The FDA has cleared multiple p24-detecting platforms in 2026, including DiaSorin’s LIAISON MUREX HIV Ab/Ag HT and Abbott’s HIV Combo Next assay for the Alinity i platform. Both represent chemiluminescent immunoassays capable of simultaneous qualitative detection of HIV p24 antigen alongside antibodies to HIV-1 and HIV-2.

A significant public health milestone came in June 2026, when Seychelles and Eritrea adopted Abbott’s Determine Antenatal Care Panel — the first WHO-prequalified rapid test integrating fourth-generation HIV detection with syphilis and hepatitis B screening from a single finger-prick sample.

Research Frontiers

Beyond commercial diagnostics, academic researchers are pursuing ultrasensitive p24 detection through microfluidic and nanomaterial-based platforms. A team from Tsinghua University recently reported a microfluidic fluorescence biosensor achieving an 18.48 pg/mL detection limit for p24, using enzyme-free signal amplification strategies. Separately, researchers demonstrated a cascaded chemiluminescence microfluidic system with antibody orientation and gold nanoparticle-mediated signal enhancement, targeting point-of-care applications in resource-limited settings.

Clinical Considerations

Despite advances, challenges persist. A 2026 study evaluating bioMérieux’s VIDAS DUO AG/AB assay against its predecessor found high rates of indeterminate p24 antigen signals during acute infection classification, underscoring the complexity of early-stage diagnosis. Additionally, recent research showed that p24 antigen was detectable only after dissociating immune complexes in samples with viral loads exceeding 10⁴ copies/mL, suggesting that circulating immune complexes may mask antigen detection in some cases.

WHO maintains performance criteria for HIV diagnostic procurement, requiring 100% sensitivity for enzyme immunoassays detecting anti-HIV-1/2 and HIV-1 p24 antigen, with specificity at or above 98%.

As manufacturers refine fourth-generation platforms and researchers push detection limits lower, p24 antigen-based diagnostics are poised to remain central to global strategies for identifying acute HIV infection and interrupting transmission chains.